SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Lumos Pharma, Inc. (LUMO) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+280.2%).
- Analyst consensus target $16.50 (+280.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LUMO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio17.24
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-4.18
Book Value / Share$0.00
Revenue / Share$0.25
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$16.50 (+280.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$27.81 |
$165.95M |
$102.86M |
62% |
| 2015 |
$-12.71 |
$36.14M |
$-40.38M |
-111.7% |
| 2016 |
$-26.45 |
$3.53M |
$-85.16M |
-2415.1% |
| 2017 |
$-20.69 |
$390K |
$-71.95M |
-18449% |
| 2018 |
$-12.97 |
$1.21M |
$-53.6M |
-4444% |
| 2019 |
$-297.07 |
$936K |
$-42.99M |
-4592.8% |
| 2020 |
$-0.84 |
$168K |
$-5.66M |
-3370.8% |
| 2021 |
$-3.65 |
$230K |
$-30.43M |
-13230.4% |
| 2022 |
$-3.71 |
$1.52M |
$-31.06M |
-2039.5% |
| 2023 |
$-4.18 |
$2.05M |
$-34.03M |
-1659.4% |
